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Abstract
Background: The Positive Transcription Elongation Factor b (P-TEFb) is a complex of Cyclin Dependent Kinase 9 (CDK9)
with either cyclins T1, T2 or K. The complex phosphorylates the C-Terminal Domain of RNA polymerase II (RNAPII) and
negative elongation factors, stimulating productive elongation by RNAPII, which is paused after initiation. P-TEFb is
recruited downstream of the promoters of many genes, including primary response genes, upon certain stimuli.
Flavopiridol (FVP) is a potent pharmacological inhibitor of CDK9 and has been used extensively in cells as a means to
inhibit CDK9 activity. Inhibition of P-TEFb complexes has potential therapeutic applications.
Results: It has been shown that Lipopolysaccharide (LPS) stimulates the recruitment of P-TEFb to Primary Response
Genes (PRGs) and proposed that P-TEFb activity is required for their expression, as the CDK9 inhibitor DRB prevents
localization of RNAPII in the body of these genes. We have previously determined the effects of FVP in global gene
expression in a variety of cells and surprisingly observed that FVP results in potent upregulation of a number of PRGs in
treatments lasting 4-24 h. Because inhibition of CDK9 activity is being evaluated in pre-clinical and clinical studies for
the treatment of several pathologies, it is important to fully understand the short and long term effects of its inhibition.
To this end, we determined the immediate and long-term effect of FVP in the expression of several PRGs. In
exponentially growing normal human fibroblasts, the expression of several PRGs including FOS, JUNB, EGR1 and
GADD45B, was rapidly and potently downregulated before they were upregulated following FVP treatment. In serum
starved cells re-stimulated with serum, FVP also inhibited the expression of these genes, but subsequently, JUNB,
GADD45B and EGR1 were upregulated in the presence of FVP. Chromatin Immunoprecipitation of RNAPII revealed that
EGR1 and GADD45B are transcribed at the FVP-treatment time points where their corresponding mRNAs accumulate.
These results suggest a possible stress response triggered by CDK9 inhibition than ensues transcription of certain PRGs.
Conclusions: We have shown that certain PRGs are transcribed in the presence of FVP in a manner that might be
independent of CDK9, suggesting a possible alternative mechanism for their transcription when P-TEFb kinase
activity is pharmacologically inhibited. These results also show that the sensitivity to FVP is quite variable, even
among PRGs.
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Background
The Positive Transcription Elongation Factor b (P-TEFb)
is a complex of CDK9 and either cyclins T1, T2 or K
[1-4]. P-TEFb is recruited to promoters by transcription
factors and/or BRD4 where it stimulates transcriptional
elongation by phosphorylating the C-terminal domain
(CTD) of RNA polymerase II (RNAPII) and the negative
elongation factors DSIF and NELF [5-7]. Although cyclin
Kw a sf i r s ti d e n t i f i e da saC D K 9p a r t n e r ,i ta p p e a r st o
prefer CDK12 and CDK13, which also play a role in elon-
gation [8]. Yet, a role for cyclin K/CDK9 has been
recently reported in maintaining genomic integrity [9,10].
Recent work has lead to the proposal that CDK9 and
CDK12/13 are the orthologs of yeast Bur1 and CTK1,
respectively [8], which play distinct roles in elongation by
RNAPII.
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significant selectivity for CDK9, as its IC50 has been found
to be about 7 times lower than that of the closest CDK
IC50 reported to date [11]. Incubation of HeLa or 293
cells for one hour with 300 nM FVP inhibits transcription
by 60-70%, as measured in run-on assays [12,13]. At a
concentration of 1 μM, treatment of OCI-Ly3 cells with
FVP results in rapid downregulation of genes with mRNA
microarray patterns similar to those obtained with the
transcriptional inhibitor Actinomycin D, and the kinetics
of mRNA downregulation reflect the half life of the
mRNAs measured [14]. However, when human T98G
cells and BJ-TERT fibroblasts were treated with 300 nM
FVP for extended periods of time (4 to 24 h) or with a
dominant form of CDK9, we observed upregulation of a
very significant number of mRNAs [15]. Among the genes
that were upregulated were a number of primary response
genes (PRGs). PRGs are genes that are induced in
response to a variety of signals and do not require de novo
protein synthesis [16]. Our findings appeared to be at
odds with recent work that has shown that expression of
PRGs responsive to LPS stimulation in macrophages cor-
relates with recruitment of cyclin T1 and CDK9 to those
genes coinciding with phosphorylation of the CTD of
RNAPII on Ser-2, and that preincubation of macrophages
with 5,6-dichloro-1-beta-D-ribofuranosyl-benzimidazole
(DRB), a CDK9 inhibitor, prevents RNAPII Ser-2 phos-
phorylation and productive elongation of these genes [17].
Since inhibition of CDK9 activity is being explored as a
therapeutic avenue in a number of diseases including
AIDS, cancer, cardiac myopathies and inflammatory pro-
cesses [11,18-20], it is important to examine the time
dependent consequences of CDK9 inhibition on gene
expression. To this end, we have determined the short
and long term effects of FVP treatment on the expression
of PRG mRNAs and the localization of RNAPII in these
genes. Our results suggest that a fraction of PRGs are
transcribed in the presence of FVP, under conditions
where phosphorylation of the CTD of RNAPII on Ser-2
and Ser-5 and the expression of other genes are clearly
inhibited.
Results
We have found that a large number of genes are upregu-
lated after treating T98G cells [15] or hTERT-immorta-
lized normal human fibroblasts (BJ-TERT fibroblasts)
(unpublished observations) with flavopiridol (FVP) for 4 h
or more. Surprisingly, some of these genes are classical
PRGs. Because the normalized data set for the BJ-TERT
fibroblasts study is much larger, all experiments and ana-
lyses described below were performed using BJ-TERT
fibroblasts (the results of the entire BJ-TERT dataset will
be reported elsewhere).
In BJ-TERT fibroblasts there were 2855 and 70 genes
upregulated more than two fold with FVP treatment or
dnCDK9, respectively. In the FVP dataset, this represents
about one fourth of all genes modulated above the 2-fold
cutoff, while the other three fourths are downregulated.
Among the upregulated genes, were genes that are
known to be regulated at the elongation phase of tran-
scription such as JUNB, FOS and some primary response
genes (PRGs) to LPS stimuli (Figure 1A and 1B). A recent
study strongly suggests that P-TEFb is required for the
expression of PRGs upon LPS stimulation of primary
macrophages [17]. However, these results could be a
priori seen in contrast with our microarray data that
showed upregulation of several of these genes upon FVP
treatment and in some cases with dnCDK9. Since Har-
greaves and collaborators classified PRGs into two groups
based on their GC promoter content: PRG-I (GC rich)
and PRG-II (GC poor), we clustered genes designated
PRG-I and PRG-II in their study using the expression
log2 ratios from our microarray data obtained with BJ-
TERT fibroblasts and visualized the results with Java-
TreeView (Figure 1A). Among the PRG-I group, were
genes downregulated upon FVP treatment at all time
points and in some cases with expression of dnCDK9
(Figure 1A left, cluster 1). However, we also observed
genes that were upregulated between 4 and 8 h of FVP
treatment (Figure 1A left, cluster 2). It was also shown
that another group of genes in clusters 3 and 4 were
downregulated early but then were strongly upregulated
at later time points (Figure 1A left, cluster 3 and 4). The
PRG-II group included 2 different clusters of genes that
behaved similarly to what was seen in the PRG-I group.
Genes in cluster 1 were downregulated upon FVP treat-
ment while genes in cluster 2 were upregulated (Figure
1A, right). Of note, visual examination of the expression
of genes in the dnCDK9 array suggested a stronger corre-
lation with the FVP arrays in the PRG-II group. This was
confirmed by hierarchical subclustering of the PRGI and
PRGII gene arrays shown in Figure 1A (Additional file 1:
Figure S1). As a control, we clustered housekeeping
genes typically used for mRNA expression normalization
when measuring expression of specific mRNAs. Their
expressions were mostly unaffected by FVP treatment or
dnCDK9 with the exception of LDHA, which was down-
regulated by 24 h of FVP treatment (Figure 1A, bottom).
Also, genes previously defined as Immediate Response
Genes (IRGs) to mitogenic stimuli [21] were clustered as
s h o w ni nF i g u r e1 B .I nt h i sg r o u p ,m o s tI R G sw e r e
downregulated with FVP and dnCDK9, but a significant
number of “classical” IRGs such as EGR1, FOS, and
CCND1, were upregulated upon FVP treatment, and in
some cases by dnCDK9. Importantly, the expression pro-
file of genes in clusters 3 and 4 of Figure 1A suggested
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Page 2 of 13Figure 1 Effect of FVP on the expression of PRGs and IRGs in BJ-TERT fibroblasts. (A) BJ-TERT fibroblasts were infected with tet-off and
dnCDK9 adenviruses (dn) in the presence or absence of tetracyclin (tet) and treated with FVP (F) as indicated. FVP treated cells were infected
with control adenoviruses (dn + tet) to eliminate viral transduction as a variable in the comparison to dnCDK9 expressing cells. The expression
ratios of FVP (F) or dnCDK9 (dn) vs. control adenoviruses in the presence of tet (dn + tet) were obtained. Hierarchical clustering was performed
for PRG-I (top left), PRG-II (top right) and housekeeping genes (bottom) and visualized with Java TreeView. PRG-I group consists of 4 clusters that
represent downregulated (cluster 1), upregulated (cluster 2) and early downregulated/later upregulated (cluster 3 and 4) genes. PRG-II group
consists of 2 clusters (clusters 1 and 2), which behave similar as clusters 1 and 2 of PRG-I group. (B) Hierarchical clustering of Immediate
Response Genes (IRGs) to mitogenic stimuli in BJ-TERT fibroblasts treated with FVP or dnCDK9 (gene arrays are in the same order as in A). A
color gradient legend indicated fold changes in expression.
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time points and subsequently be upregulated, since the
earliest FVP treatment time point in the microarray ana-
lysis was 4 h. Therefore, we rationalized that the genes in
cluster 2 could potentially be downregulated prior to the
4 h time point collected. To test this possibility, a new set
of time course experiments where BJ-TERT cells were
treated with FVP for periods of time as short as 30 min
was performed. The expression levels of these genes were
determined by Q-RT-PCR as described in the Methods
section.
Q-RT-PCR experiments validate the microarray results and
unveil genes whose expression is potently and rapidly
inhibited by FVP and subsequently upregulated
For this analysis we selected the following PRG-I genes;
EGR1, JUNB, and FOS (Figure 1A), and the IRG Cyclin
D1 (Figure 1B), which are upregulated at 8 and 24 h of
FVP treatment. We also selected the IRG response gene
GADD45B, which is downregulated 4 and 8 h and subse-
quently upregulated at 24 h (Figure 1B). In addition, we
selected two genes from the microarray analyses that were
downregulated at all time points: HEXIM1 and MCL1. Of
n o t e ,H E X I M 1i sak n o w nC D K 9t a r g e tg e n e[ 2 2 ]a n d
MCL1 is an IRG [21]. Finally, we also selected ALDOA, a
housekeeping gene whose expression was found to be
unchanged in the microarray analysis (Figure 1A, bottom
panel).
Exponentially growing BJ-TERT fibroblasts were trans-
duced with control adenoviruses (Ad-CRE) and treated
with 300 nM FVP for 0, 30’,1 ,2 ,4 ,8 ,1 6a n d2 4h .T h e
rational for transducing the cells with control adenoviruses
in this experiment was that cells treated with FVP in the
microarray experiments had previously been transduced
with adenoviruses expressing no transgene to allow com-
parison to cells transduced with adenoviruses directing the
expression of dnCDK9. After FVP treatment, BJ-TERT
fibroblasts were collected at indicated time points and
RNA was extracted. Q-RT-PCR analyses were then per-
formed to determine transcript levels using Taqman
probes specific for the genes listed above and represented
as a fold change value of levels normalized to 1 at time
zero (Figure 2A). The results from Q-RT-PCR and micro-
array analyses were comparable as it was shown that FOS,
EGR1, JUNB and GADD45B were upregulated at late time
points. However, they were all sharply and rapidly downre-
gulated upon FVP treatment as early as 30 min (Figure
2A). CCND1 appeared to be upregulated without early
downregulation. In contrast, MCL1 and HEXIM1 were
downregulated with slower kinetics and remained down
through the time course. As expected, there was no
change in the expression of ALDOA.
To make the visualization of the comparison of micro-
array and Q-RT-PCR data clearer, Q-RT-PCR values
from this experiment were converted to log2 ratios and
represented with Java-TreeView with the same color gra-
dient used in the microarray data (Figure 2B). This repre-
sentation allows concise visualization and clusters the
genes according to similar kinetics of expression. To
compare the exact same time points in the microarray
and Q-RT-PCR data, the microarray data and log2 con-
verted Q-RT-PCR data for 4, 8, and 24 h of FVP treat-
ment were visualized with Java-TreeView. Figure 2C
demonstrates the similarity of the expression data
obtained by microarray and Q-RT-PCR analysis. Next,
this experiment was repeated under the same conditions,
except that transduction with control adenoviruses was
omitted. We found that the kinetics of downregulation/
upregulation of all these genes was very similar (Addi-
tional file 2: Figure S2), indicating that viral transduction
does not significantly affect the expression of these genes
in BJ-TERT fibroblasts. Altogether these experiments
demonstrate that several classical PRG/IRGs are rapidly
downregulated but subsequently recover and are upregu-
lated in the presence of FVP. Of note, these genes are
upregulated at the same time that other genes are maxi-
mally downregulated (Figure 2B) and phosphorylation of
the CTD of RNAPII on Ser-2 and Ser-5 remains inhibited
(see below).
Certain PRG/IRGs are significantly expressed in the
presence of FVP during a mitogenic response
FOS, EGR1, JUNB and GADD45B are all known to be pri-
mary response genes to mitogenic stimuli as their tran-
scripts accumulate in response to mitogenic stimuli in the
absence of protein synthesis [21]. The experiments
described in the previous section were done using expo-
nentially growing BJ-TERT fibroblasts in the presence of
complete medium with serum. To determine the effect of
FVP in the expression of the PRG/IRGs in response to
mitogenic stimulation, we performed experiments of
serum starvation followed by mitogenic stimulation in the
presence and absence of FVP. BJ-TERT fibroblasts were
serum starved for three days with serum free medium.
Serum starved BJ-TERT fibroblasts were treated either
w i t h3 0 0n MF V Po rv e h i c l e( D M S O )1 5m i np r i o rt o
serum stimulation. Following serum stimulation, cells
were collected at the time points indicated in Figure 3.
First, we determined the effect of FVP upon serum sti-
mulation of BJ-TERT cells on the cell cycle by flow cyto-
metric analysis of propidium iodide stained cells and by
western blot analysis of cell cycle markers (Figure 3A and
3B). Serum re-stimulated BJ-TERT cells exhibited 36% of
cells in S phase 22 h post stimulation and cells reached
the G2/M phases by 30 h. In contrast, cells re-stimulated
with serum in the presence of FVP remained with a
G0/G1 DNA content by 30 h. Thus, FVP completely
blocked entry into S phase. For parallel western blot
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Page 4 of 13analysis, BJ-TERT fibroblasts were collected at additional
time points as indicated. FVP inhibited expression of
Cyclin D1, and completely blocked upregulation of p107,
an E2F-dependent gene product. This indicates that cells
are likely blocked prior to the restriction point in G1 or
earlier, as passage through the restriction point is
Figure 2 Biphasic effect of FVP in the expression of certain PRG/IRGs. (A) BJ-TERT fibroblasts were treated with 300 nM FVP as described in
Figure 1A and the expression of indicated mRNAs was determined by Q-RT-PCR analysis. Data was represented as a fold change value with
respect to mRNA expression at time zero. (B) Q-RT-PCR data was converted to log2 ratios and visualized with the same color scale used in
microarray analysis using Java-TreeView. (C) Comparison of the log2 ratios obtained from microarray and Q-RT-PCR data at the same time points.
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sion (Figure 3B) [23]. The effects of FVP in transcription
were monitored by determining the phosphorylation state
of RNAPII. CDK9 is thought to phosphorylate Ser-2, while
Ser-5 is thought to be phosphorylated by CDK7 and other
kinases. FVP potently inhibited Ser-2 and Ser-5 phosphor-
ylation of RNAPII within 2 h of treatment, and impor-
tantly, phosphorylation remained inhibited through the
time course, which is consistent with a general block in
transcription. Also, consistently with the effects of FVP on
the expression of MCL1 mRNA, we observed a block on
MCL1 protein upregulation and sharp downregulation
below its basal levels in quiescent cells (Figure 3B).
To exclude the possibility that the concentration of FVP
(300 nM) used in these experiments inhibited G1 CDKs,
we determined the effects of FVP at different concentra-
tions ranging from 10 nM to 10 μM on the phosphoryla-
tion of pocket proteins (pRB, p107 and p130), as
compared to RNAPII CTD phosphorylation on Ser-2 and
Ser-5 (Figure 3). In agreement with our previous work,
300 nM FVP resulted in inhibition of both Ser-2 and Ser-5
phosphorylation [15], while dephosphorylation of pocket
proteins was only noticeable at a FVP concentration of
10 μM.
Next, we performed three independent serum starvation
experiments to determine the effects of FVP on the tran-
script levels of various PRGs. BJ-TERT fibroblasts were
serum starved for three days and subsequently stimulated
Figure 3 Certain PRG/IRGs are significantly expressed in the presence of FVP during a mitogenic response. (A) Effects of FVP in the cell
cycle were determined by FACS of Propidium Iodide(PI)stained cells. The percent of cells in S phase is indicated at the top of each panel. BJ-
TERT fibroblasts were treated with either DMSO or 300 nM FVP followed by serum stimulation for 0, 14, 22 and 30 h and stained with PI. (B)
Western blot analysis of cell cycle progression, transcription markers and MCL1. BJ-TERT fibroblasts were harvested and lysed. Ten microgram of
protein was resolved by 8% polyacrylamide/SDS gel electrophoresis, transferred to a PVDF membrane and specific antibodies were used to
detect proteins, as indicated above. (C) 300 nM FVP inhibits phosphorylation of the CTD of RNAPII on Ser-2 and Ser-5 without affecting the
phosphorylation state of pocket proteins. Exponentially growing BJ-TERT fibroblasts were treated with FVP at 10 nM, 30 nM, 100 nM, 300 nM, 1
μM and 10 μM for 2 and 4 h. Whole cell lysates were resolved by 6% SDS/PAGE and immunoblotted with antibodies to the indicated proteins/
phosphorylation sites. Solid and dashed arrows at the bottom indicate the concentration of FVP leading to dephosphorylation of RNAPII and
pocket proteins, respectively. The asterisk indicates a crossreacting band recognized by the anti-p130 antibody. (D) mRNA levels of selected
genes at the indicated time points were detected by Q-RT-PCR. The results of three different experiments are shown. Data are represented as a
fold change value of levels normalized to 1 at time zero. The results of three different experiments are shown.
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Page 6 of 13with serum in the presence of FVP or vehicle (DMSO).
Figure 3D shows rapid and potent serum-dependent sti-
mulation of FOS, EGR1, JUNB and GADD45B, as would
be expected from any highly inducible PRG in one of
these three experiments. FOS and EGR1 peak at 30 to 60
min post stimulation, while GADD45B and JUNB peak at
least 30 min later. Induction of these genes is more potent
for FOS that reaches up to 350 fold, being near 10-30 fold
for the other PRG genes. The expression of these four
genes goes back to the expression level seen in quiescent
cells between 4 and 22 h of serum stimulation. MCL1
behaves similarly, peaking about 1 h, but it is only upregu-
lated 4 to 6 fold, while CCND1 peaks later and is upregu-
lated to a lower extent (Figure 3D).
FVP inhibits the expression of all these genes. In the
case of FOS, this inhibition is extremely potent, if not
complete. MCL1 and CCND1 are also clearly inhibited,
and in the case of MCL1, expression goes clearly below
the basal levels observed in quiescent cells. Importantly,
GADD45B, JUNB and EGR1 are all induced at significant
levels in the presence of FVP, although there is clear varia-
bility within the experiments (Figure 3D). GADD45B is
upregulated between 5 and 17 fold by 22 h, and induction
over basal levels is first seen 1 h post stimulation. JUNB is
induced 4-6 fold, peaking 4 h in the presence of FVP. On
the other hand, EGR1 is the most variable; its expression
is completely blocked by FVP in experiment 1 (Figure 3D,
left panel), but potently upregulated in experiment 2 (Fig-
ure 3D, middle panel). These results suggest that the activ-
ities inhibited by FVP, which include CDK9, are clearly
important for the mitogen induced transcription program.
However, these results also show that the sensitivity of
genes to FVP is highly variable and that some genes can
be significantly expressed in the presence of FVP, when
RNAPII phosphorylation is clearly inhibited.
Some PRGs are transcribed in the presence of FVP
The experiments described above measure the expression
of particular mRNAs, but they are not a direct measure-
ment of transcription. The levels of any particular mRNA
are the result of an equilibrium between RNA synthesis
and degradation. Thus, it is conceivable that the induc-
tion in the expression of some PRG/IRGs is the result of
potent RNA stabilization rather than effective transcrip-
tion in the presence of FVP. To determine the direct
effects of FVP in the presence of RNAPII in the tran-
scribed region of FOS, EGR1 and GADD45 in vivo,w e
performed chromatin immunoprecipitation (ChIP) assays
with anti-RNAPII antibodies. Localization of RNAPII
n e a rt h ep r o m o t e ra n di nt h eb o d yo ft h eg e n ei sam e a -
surement of how actively a gene is being transcriptionally
elongated by RNAPII [24-28]. BJ-TERT fibroblasts were
serum starved for three days, followed by vehicle
(DMSO) or 300 nM FVP treatment 30 min prior to
serum stimulation. Following serum stimulation, cells
were fixed in 1% formaldehyde/PBS and collected at 0, 15
min, 4 and 22 h. ChIPs were performed with antibodies
to RNAPII and control IgGs, as described in the Methods
section. The Q-PCR data is represented as a percentage
of input chromatin amplified with each primer set (PS) in
each ChIP. Four sets of primers were used for each
selected PRG: a set of primers upstream of the promoter
(A), a set downstream of the promoter just at the begin-
ning of the first exon (C), a set in the body of the gene
and a set presumably downstream of the gene (H) (Figure
4, top). Figure 4 shows the ChIP results for total RNA
polymerase (RNAPII) at the FOS, EGR1 and GADD45B
loci in the presence or absence of FVP. In the case of
FOS, transcription elongation is not detected in serum
starved quiescent cells, as no RNAPII is localized in the
body of the gene (Figure 4, PS-E, absence of blue bar). A
peak of RNAPII is localized downstream of the promoter
(Figure 4, PS-C, blue bar) indicating that transcription is
initiated but there is no elongation. Stimulation with
serum for 15 min results in increased recruitment of
RNAPII downstream of the promoter (Figure 4, left
panel, PS-C, red bars). In addition, RNAPII is detected
throughout the gene body (Figure 4, PS-E, red bars) 15
min post serum stimulation, indicating active transcrip-
tion elongation. RNAPII remains bound near the promo-
ter site at 4 and 22 h post serum stimulation, but RNAPII
is not detected through the gene body, demonstrating
that FOS is not transcriptionally elongated by RNAPII at
4 and 22 h post serum stimulation (Figure 4, left panel,
PS-C and E). In the EGR1 gene, elongating RNAPII is
also not detected in serum starved fibroblasts (Figure 4,
middle panel, PS-E, absence of blue bar). However, EGR1
appears to be elongated by RNAPII 15 min post serum
stimulation, as high levels of RNAPII are recruited to the
body of this gene (Figure 4, middle panel, PS-E and H,
red bars). Similarly to FOS, EGR1 is not elongated by
RNAPII at 4 and 22 h post serum stimulation, as RNAPII
is not detected in the gene body (Figure 4, middle panel,
red bars, PS-E and H). In the case of GADD45B, there is
little transcription detected in serum starved cells, but
elongation by RNAPII appears to be detected 15 min
post mitogenic stimulation (Figure 4, right panel, red
b a r s ,P S - Ea n dH ) .I nc o n t r a s tt oF O Sa n dE G R 1 ,
GADD45B also appears to be elongated at 4 h of mito-
genic stimulation, as RNAPII is detected with PS-E and
H (Figure 4, right panel). Altogether confirms that these
genes are highly inducible by mitogenic signaling, and
subsequently downregulated to basal or near basal
expression levels.
FVP inhibited elongation by RNAPII of FOS 15 min
post serum stimulation by 2 fold, but elongation was
completely blocked at 4 and 22 h (Figure 4 left panel,
green bars, PS-E). Of note, RNAPII remained bound just
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ment, indicating that FVP does not prevent basal tran-
scription initiation, although it eliminates the increased
recruitment observed with serum (Figure 4, PS-C, com-
pare three bars). In contrast to FOS, RNAPII is detected
at all time points with PS-E of EGR1 upon FVP treat-
ment, suggesting that EGR1 is transcriptionally elongated
even in the presence of FVP. In addition, RNAPII recruit-
ment is increased on EGR1 downstream of the promoter
site at 4 and 22 h of FVP treatment (Figure 4, middle
panel, green bars). GADD45B also appears to be tran-
scriptionally elongated at 15 min, and 4 and 22 h of FVP
treatment (Figure 4, right panel, green bars) but RNAPII
levels are relatively much higher at 4 and 22 h of FVP
treatment immediately downstream of the promoter.
In summary, FOS is transcriptionally elongated at
early time points of serum stimulation but this gene is
not elongated at later time points either in the presence
or absence of FVP. In contrast, EGR1 and GADD45B
are transcriptionally elongated at early time points upon
serum stimulation; however, these genes are also tran-
scriptionally elongated upon FVP treatment at all time
points. Of note, these results are consistent with the
mRNA expression effects of FVP in these genes as
determined by microarray and Q-RT-PCR analysis. Con-
sidering that the expression of other genes is completely
Figure 4 Some PRGs are transcribed in the presence of FVP. ChIP assays were performed, as described in the Methods section. Percent of
input chromatin specifically immunoprecipitated with anti-RNAPII antibodies is represented at 0 and 15’ (upper graph), 0 and 4 h (middle graph)
and 0 and 22 h (bottom graph) for each primer set. The upper panel depicts the gene structure of FOS, EGR1 and GADD45B and the position of
the corresponding primer pair sets (see text for details).
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inhibition of RNAPII, Ser-2 and Ser-5 phosphorylation
( F i g u r e3 B ) ,i ta p p e a r sp o s s i b l et h a tb o t hE G R 1a n d
GADD45B posses alternative mechanisms of transcrip-
tional elongation independent of CDK9 and other FVP-
sensitive kinases.
Discussion
Hierarchical clustering analysis of microarray expression
ratios of select PRG/IRGs revealed that a subset of these
genes were upregulated between 4 and 8 h of FVP treat-
ment and maximally upregulated by 24 h. This at first
appeared to be at odds with recently published work by
Hargreaves et al (2009). The authors of this study have
shown that stimulation of primary macrophages with
LPS leads to rapid upregulation of a number of PRGs.
They have shown that unstimulated PRGs exhibit paused
RNAPII with Ser-5 phosphorylation at the promoters,
but Secondary Response Genes (SRGs) do not. Their
data also show that LPS stimulation leads to recruitment
of CDK9 and Cyclin T1, and RNAPII with Ser-2 phos-
phorylation and this is blocked by DRB, a pharmacologi-
cal inhibitor of CDK9. Our microarray analysis of PRG/
IRGs has led to the identification of a cluster of about a
third of these genes that are upregulated upon FVP treat-
ment. This includes two classical PRGs, EGR1 and FOS
that we selected for further study. Interestingly, genes in
cluster 3 and 4 (Figure 1A) were found to be downregu-
lated by 4 h of FVP treatment and subsequently upregu-
lated, suggesting the possibility that PRGs are transiently
downregulated by FVP.
Our q-RT-PCR data confirmed both the upregulation
of genes in cluster 2 at late FVP time points and the
hypothesis of the transient effects of FVP. In Figure 2A
and 2B, it is clearly shown that EGR1, FOS, GADD45B
and JUNB are rapidly downregulated by 30 min of treat-
ment and go back to basal levels between 4 and 8 h, and
then, are rapidly upregulated. One possible interpretation
of these results is that FVP is at least partially metabo-
lized in the cell, and thus, these genes are no longer
inhibited. However, a number of observations argue
against this possibility. First, RNAPII phosphorylation on
Ser-2 and Ser-5 remains inhibited through the time
course. Second, several PRG/IRGs remain inhibited
through the time course. Third, genes in cluster 2 are not
just going back to basal levels, but are clearly upregu-
lated, often by several fold, under conditions in which
housekeeping genes are not modulated. Fourth, previous
work has shown genes that are transcribed independently
of CDK9, such as certain p53 target genes [29] and the
U2 snRNA and histone H2b genes [30].
To investigate this further, it was necessary to use a
more defined model of primary response to stimulus.
Since EGR1, FOS, JUNB and GADD45B are all responsive
to serum stimulation [21,28,31], we selected this system.
Our data clearly shows that FVP, at concentrations that do
not inhibit pocket protein phosphorylation, completely
blocks DNA synthesis and the upregulation of cell cycle
markers, such as the expression of the E2F-dependent pro-
duct p107, suggesting that cells are arrested before the
restriction point in G1 or even earlier at the G0/G1 transi-
tion [23]. This arrest is preceded by potent inhibition of
total Ser-2 and Ser-5 phosphorylation on the CTD of
RNAPII, which remains low throughout the time course.
Under these conditions, three genes (GADD45B, JUNB
and EGR1) exhibited time dependent upregulation of their
expression over untreated cells in the presence of FVP.
Although there was variability between experiments, the
trend was similar. In contrast, FOS expression was com-
pletely blocked under these conditions. Consistent with
these results, RNAPII ChIP localization assays demon-
strated the presence of RNAPII in the body of the EGR1
and GADD45B genes, at 4 and 24 h of serum stimulation
in the presence of FVP. In contrast, RNAPII could not be
detected in the body of the FOS gene at these time points.
These data strongly suggest that the upregulation of EGR1
and GADD45B expression seen in the presence of FVP is
due to active transcription. Another interesting observa-
tion is the accumulation of RNAPII in chromatin down-
stream of the promoter near the beginning of exon 1 of
EGR1 and GADD45B. This accumulation can be due to
increased recruitment of RNAPII under conditions of
stress (sustained inhibition of transcription), but it could
also indicate increased elongation of transcripts that is not
fully productive. Distinguishing between these possibilities
would require further experimentation addressing the
recruitment of transcription factors and the phosphoryla-
tion of RNAPII using ChIP.
Two studies published when this work was being com-
pleted have examined the effects of pharmacological inhi-
bition of CDK9 in the expression of PRGs. In the first of
these studies, FVP dramatically inhibited the expression of
F O S ,E G R 1 ,E G R 2a n dE G R 3u p o n3 0m i no fs e r u ms t i -
mulation of HCT116 cells [28]. ChIP showed inhibition of
RNAPII localization and diminished Ser-2 and Ser-5 phos-
phorylation of RNAPII in the body of the EGR1 and EGR2
genes. While this study did not determine the effects of
FVP at later time points, they observed increased RNAPII
at the promoter in the presence of FVP at 30 min post
serum stimulation. This effect might be related to our
observation of increased RNAPII near exon 1 of EGR1
gene at 4 and 24 h of serum stimulation. The second
study utilized halogenated imidazole derivatives that
blocked transcriptional elongation and, at least one of
them, CDK9 activity [31]. In this study, both compounds
potently inhibited the transcription of PRGs. However, the
study did not analyze the effects of these compounds at
later time points.
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of FVP on gene expression globally. Both studies used
concentrations of FVP of 1 μM. This concentration of
FVP is very toxic, and it is unclear if any other CTD
CDKs are inhibited under these conditions. Lam et al.
showed that 1 μM FVP results in the rapid downregula-
t i o no fg e n e su pt o8h[ 1 4 ] .R a h let al. using ChIP-seq
showed that 1 μM FVP completely blocks localization of
RNAPII in the body of actively transcribed genes, but
does not affect localization of RNAPII near the promoter
[27]. If a concentration of 1 μM FVP is selective for
CDK9 inhibition in cells, these data would mean that
CDK9 is essential for transcriptional elongation of a large
proportion of genes. Of note, Chao and Price showed
previously that FVP treatment (300 nM) of HeLa cells
inhibits transcription in in vitro run on assays by 70%
[12]. Again, if 300 nM FVP selectively inhibits CDK9,
these data would demonstrate that CDK9 inhibition halts
transcription of most genes. This could be a direct effect
on genes that require CDK9 for elongation, i.e. PRGs,
and indirect on those genes not transcribed because of
rapid depletion of inducible transcription factors.
Ser-2 and Ser-5 phosphorylation of the CTD of RNA-
PII have been linked to recruitment of histone chaper-
ones such as Spt6 and/or histone modifications,
including H3K36me3, which may play roles in nucleo-
some disassembly and assembly during elongation by
RNAPII [32,33]. Thus, inhibition of RNAPII Ser-2 and
Ser-5 phosphorylation at certain genes may prevent
nucleosome reassembly and facilitate sustained transcrip-
tion with a delay.
Finally, it is also conceivable that after a potent inhibi-
tion of transcriptional elongation that quickly depletes the
cell from PRG/IRGs and other highly inducible transcrip-
tion factors, the cell might require a boost in the expres-
sion of some of these PRG/IRGs. Gene expression might
differentially oscillate before reaching a new transcrip-
tional equilibrium. Some gene expression oscillation might
be CDK9 independent, occurring while CDK9 is still effec-
tively inhibited. Other changes might follow the expression
of required PRG transcription factors. Understanding this
fully will require more extensive studies using ChIP and/
or ChIP-seq for RNAPII phosphorylated on Ser-2 and Ser-
5, as well as recruitment of CDK9 and other RNAPII
CDKs using FVP and more selective inhibitors of CDK9.
Future gene expression profiling experiments should
include short treatments with pharmacological inhibitors
of CDK9. This will allow more precise identification of the
groups of genes that are co-modulated in a time depen-
dent manner.
Understanding the effects of CDK9 inhibition on gene
expression is of considerable interest because of therapeu-
tic implications. CDK9/Cyclin T1 activity is essential for
HIV transcription, and hence, replication [1,13,34-37].
CDK9 activity is upregulated in hypertrophic cardiomyo-
pathy [38]. Moreover, Mixed Lineage Leukemia [39] and
certain ER-positive breast cancer [40,41] exhibit deregula-
tion of P-TEFb activity. Thus, understanding the conse-
quences of inhibiting CDK9 activity on gene expression
over time is important. Our data suggest the possibility of
a stress response to the effects of inhibiting transcriptional
elongation that may result in the transcription of certain
genes in a CDK9 independent manner. Some of the genes
that would fit this category would be the PRG/IRG EGR1
and GADD45B, but the members of PRG/IRGs behaving
in this manner are like to be larger.
Conclusions
We have shown that certain PRGs are transcribed in the
presence of FVP in a manner that appears independent of
CDK9 suggesting the existence of a possible alternative
mechanism for their transcription when P-TEFb kinase
activity is pharmacologically inhibited. This could be part
of a stress response to the effects of inhibiting transcrip-
tional elongation. Understanding the effects of CDK9 inhi-
bition on gene expression over time is of considerable
interest because it is a potential therapeutic target in a
number of diseases including AIDS, certain cancers,
inflammatory processes and hypertrophic cardiomyopathy.
Methods
Cell culture and treatments
Human BJ-TERT fibroblasts are normal BJ fibroblasts
immortalized with human Telomerase Reserve Transcrip-
tase (hTERT) [42]. BJ-TERT fibroblasts were maintained
in Dulbecco’s Modification of Eagle’s Medium (DMEM)
(Cellgro) supplemented with 10% Fetal Bovine Serum
(FBS) (Gemini) and 100 U/ml penicillin and 100 μg/ml
streptomycin (Gemini). Cells were grown at 37°C in 5%
CO2. For primary response gene assays, BJ-TERT fibro-
blasts were grown up to 50-70% confluence and starved in
serum-free medium for 72 h as described in [43]. CDK9
was pharmacologically inhibited by adding Flavopiridol
(FVP). FVP was prepared in DMSO at a concentration of
10 mM then dissolved in PBS to 100 μMa n da d d e dt ot h e
medium to give a final concentration of 300 nM. Control
cells were treated with the same concentration of DMSO
(Dimethyl sulfoxide) dissolved in PBS. Thirty minutes
after the addition of FVP or DMSO, serum starved cells
were stimulated with serum and collected at the times
indicated in the results section. Flow cytometric cell cycle
analysis was done as previously described [43]. Where
indicated, FVP treated cells were preinfected with control
adenoviruses Ad-T-dnCDK9 plus Adeno-X™ Tet-Off™
in the presence of tetracyclin (dn + tet) to eliminate viral
transduction as a variable in the comparison to dnCDK9
expressing cells (transduced with Ad-T-dnCDK9 plus
Adeno-X™ Tet-Off™ in the absence of tetracyclin (dn)).
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plus Adeno-X™ Tet-Off™ adenviruses (dn) in the pre-
sence or absence of tetracyclin (tet) essentialy as previously
descrived [15] and then treated with FVP for the times
indicated in the figures.
Protein analyses
Cells were lysed with ice-cold lysis buffer (50 mM Tris-
HCl (pH 7.4), 5 mM EDTA, 250 mM NaCl, 50 mM NaF,
0.1% Triton X-100, 0.1 mM Na3VO4, 2 mM PMSF, 10 μg/
ml leupeptin, 4 μg/ml aprotinin, and 40 μg/ml pepstanin).
Proteins were resolved by 8% polyacrylamide/SDS gel elec-
trophoresis, and transferred to a polyvinylidene difluoride
(PVDF) membrane (Immobilon-FL, Millipore) in 10 mM
CAPS/10% methanol buffer (pH 11). Western blot ana-
lyses were performed as described previously [15]. Bands
were visualized by using Western Lighting Plus ECL
reagent (Perkin Elmer) and X-Ray film or imaging with
FluorChemQ Imaging System (Alpha Innotech). For Wes-
tern blot analyses the following antibodies were used:
Anti-RNAPII (A300-653A), anti-Ser-2 (A300-654A), and
anti-Ser-5 (A300-655A) rabbit polyclonal antibodies were
obtained from Bethyl. Anti-MCL1 (sc-819), anti-Cyclin D1
(sc-8396), anti-CDK2 (sc-163), anti-Cyclin E (sc-481), and
anti-p107 (sc-318) rabbit polyclonal antibodies were
obtained from Santa Cruz Biotechnology.
Microarray cluster analysis
The Affymetrix Human Gene 1.0 ST transcript data set
utilized in the cluster analysis described in this report will
be reported elsewhere. Hierarchical cluster analysis (Clus-
ter version 3.0, [44]) was performed to cluster genes using
average linkage clustering and visualized with Java Tree-
View, version 1.0.13 as in [15].
Q-RT-PCR and Q-PCR
RNA was isolated from BJ-TERT fibroblasts by using the
RNeasy Extraction Kit (Qiagen). RNA expression was
determined in 96 well plates using the TaqMan 1 Step
PCR Kit (Applied Biosystems) and 20 μl reactions contain-
ing specific TaqMan probes. mRNA levels were deter-
mined using an ABI Prism 7000 RT-PCR system (Applied
Biosystems). Taqman probes used in this study are as fol-
low: JUNB (Hs00357891_s1), ALDOA (Hs00605108_g1),
HEXIM1 (Hs0053918_s1), GADD45B (Hs00169387_m1),
CCND1 (Hs99999004_m1), MCL1 (Hs03043899_m1),
FOS (Hs01119256_g1), EGR1 (Hs00152928_m1). A
GAPDH probe was used for normalization. Threshold
Cycle (CT) values for each sample were normalized with
GAPDH CT values. Then, a second normalization was
performed by subtracting normalized values of each time
point from the control normalized value per each gene.
SYBR Green qPCR Mix (Fermentas) was used to
determine relative DNA amounts in input chromatin
samples and ChIPs (anti-RNAPII) and IP mock (IgG) in
96 well plates using the StepOnePlus PCR instrument
(Applied Biosystems). RNAPII IP and mock ChIP CT
values were normalized with input CT values to obtain
the percentage of input values separately for each pri-
mer set. The percentage of input was calculated, mock
ChIP values were subtracted from RNAPII ChIP values
and results were visualized via Excel graphs.
Additional file 3: Table S1 shows primers for FOS and
EGR1 (Donner, et al, 2010), and GADD45B genes. The
Reference Sequence (RefSeq) of human GADD45B was
obtained from ECR browser http://ecrbrowser.dcode.org.
Four different primer pairs were designed using Oligo Per-
fect™ Designer http://www.invitrogen.com to amplify the
following sequences: Primer set A: upstream of the gene;
Primer set C: 5’UTR close to Exon 1; Primer set E: Exon 3;
Primer set H: downstream of the gene.
Chromatin immunoprecipitation (ChIP)
ChIP experiments were carried out as described in [28].
BJ-TERT fibroblasts were grown in 10 cm plates up to 50-
70% confluence. Serum-starved cells were treated with
FVP or DMSO, and then stimulated with serum as
described in the cell culture section. Cells were fixed with
1% formaldehyde/PBS for 15 min at room temperature.
The cross-linking reaction was stopped by adding glycine
(0.125 M). Cells were then washed twice with cold PBS,
and harvested with complete Szak’s RIPA buffer (150 mM
NaCl, 1% Nonidet P-40, 0.5% deoxycholate, 0.1% SDS,
50 mM Tris-HCl pH 8, 5 mM EDTA, Protease Inhibitor
Cocktail (Roche), 10 mM PMSF). Cells were then soni-
cated for 30 cycles of 15 s, followed by 1 min rest on ice
(50% duty cycle). Sonicated chromatin was cleared by cen-
trifugation. The amount of protein in the cell was quanti-
fied by using the BCA Protein assay kit (Thermo
Scientific). Sonicated DNA was about 300 bp. Sheared
chromatin extracts were pre-cleared with Protein A
sepharose beads. Protein A beads loaded with antibodies
and blocked with BSA and Salmon Sperm DNA were
incubated with chromatin overnight at 4°C on a rotator.
The immunoprecipitated chromatin was washed twice
with incomplete RIPA buffer (without PMSF and Protease
Inhibitor cocktail), four times with Szak IP Wash Buffer
(100 mM Tris HCl pH 8.5, 500 mM LiCl, 1% Nonidet P-
40, 1% deoxycholate), then twice again with incomplete
RIPA buffer and twice with cold 1X TE. The cross-links
were then reversed by adding Talianidis Elution Buffer
(1.5X) (70 mM Tris HCl pH 8, 1 mM EDTA, 1.5% SDS),
and NaCl (200 mM final) overnight at 65°C. Samples were
then treated with 20 μg of Proteinase K (Qiagen) for
30 min at 45°C, extracted with Phenol/Chloroform and
ethanol precipitated. The pellet was resuspended in water
and analyzed by Q-PCR as described above. The following
antibodies were used for ChIP: Anti-RNAPII (8WG16)
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Page 11 of 13monoclonal antibodies from Covance and mouse mono-
clonal IgGs (sc-2025) from Santa Cruz Biotechnology.
Additional material
Additional file 1: Figure S1. The highest correlation between
downregulated PRGs by dnCDK9 and FVP occurs in the cluster 1 of
PRGII. Hierarchical clustering of both genes and gene arrays was
performed for the indicated PRG-I (left) and PRG-II (right) clusters
designated in Figure 1A, and visualized with Java TreeView. The array
node correlation is shown adjacent to each node (blue digits). A color
gradient legend indicates fold changes in expression.
Additional file 2: Figure S2. The Biphasic effect of FVP in the
expression of certain PRG/IRGs in BJ-TERT fibroblasts is independent of
whether cells are preinfected with control adenoviruses. (A) BJ-TERT
fibroblasts were treated with 300 nM FVP and the expression of
indicated mRNAs was determined by Q-RT-PCR analysis. Data was
represented as a fold change value with respect to mRNA expression at
time zero essentially as described in Figure 2A.
Additional file 3: Table S1. Forward and Reverse Primers for ChIP
Analyses for FOS and EGR1 genes (Donner et al, 2010) and the GADD45b
Gene.
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